Journal of Clinical Oncology, Vol 15, 2866-2872, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival

F Graus, J Dalmou, R Rene, M Tora, N Malats, JJ Verschuuren, F Cardenal, N Vinolas, J Garcia del Muro, C Vadell, WP Mason, R Rosell, JB Posner and FX Real
Service of Neurology, Hospital Clinic i Provincial, Barcelona, Spain. graus@medicine.ub.es

PURPOSE: Anti-Hu antibodies (HuAb) recognize antigens expressed by neurons and small-cell lung cancer (SCLC). High titers of HuAb were initially reported in serum from patients with paraneoplastic encephalomyelitis/sensory neuropathy (PEM/SN) and SCLC. Preliminary studies have indicated that some SCLC patients without PEM/SN harbor low titer of HuAb in their serum, and that the SCLC of these patients may grow more indolently. Based on these observations, we conducted a multicenter prospective study of SCLC patients without PEM/SN to determine the incidence and prognostic implications of HuAb. METHODS: Serum samples were collected at diagnosis of SCLC in 196 patients without PEM/SN. HuAb were determined by immunoblot of purified recombinant HuD antigen. RESULTS: HuAb were detected in 32 (16%) of the 196 patients. Of the 170 patients who received treatment for the tumor, 27 (16%) were HuAb positive. HuAb was associated with limited disease stage (59.3% v 38.6%; P = .047), complete response to therapy (55.6% v 19.6%; P < .001), and longer survival (14.9 v 10.2 months; P = .018). In a logistic regression analysis, HuAb status was an independent predictor of complete response induction. The probability of achieving a complete response was more than five times higher in HuAb-positive than in HuAb-negative patients (odds ratio, 5.4; 95% confidence interval, 1.71 to 16.89; P = .004). Cox multivariate analysis indicated that HuAb status was not independently associated with survival. CONCLUSION: The presence of HuAb at diagnosis of SCLC is a strong and independent predictor of complete response to treatment. This feature accounts for the association between HuAb and longer survival.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. J. Titulaer, R. Klooster, M. Potman, L. Sabater, F. Graus, I. M. Hegeman, P. E. Thijssen, P. W. Wirtz, A. Twijnstra, P. A.E. S. Smitt, et al. SOX Antibodies in Small-Cell Lung Cancer and Lambert-Eaton Myasthenic Syndrome: Frequency and Relation With Survival J. Clin. Oncol., September 10, 2009; 27(26): 4260 - 4267. [Abstract] [Full Text] [PDF]

				V. Katsanou, S. Milatos, A. Yiakouvaki, N. Sgantzis, A. Kotsoni, M. Alexiou, V. Harokopos, V. Aidinis, M. Hemberger, and D. L. Kontoyiannis The RNA-Binding Protein Elavl1/HuR Is Essential for Placental Branching Morphogenesis and Embryonic Development Mol. Cell. Biol., May 15, 2009; 29(10): 2762 - 2776. [Abstract] [Full Text] [PDF]

				S Watanabe, J Tanaka, T Ohta, H Yoshizawa, and F Gejyo Paraneoplastic neurological syndrome and polyglandular autoimmune syndrome type 2 in a case of small cell lung cancer Thorax, December 1, 2008; 63(12): 1118 - 1119. [Abstract] [Full Text] [PDF]

				L. Sabater, M. Titulaer, A. Saiz, J. Verschuuren, A. O. Gure, and F. Graus SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome Neurology, March 18, 2008; 70(12): 924 - 928. [Abstract] [Full Text] [PDF]

				P. Sabbatini and K. Odunsi Immunologic Approaches to Ovarian Cancer Treatment J. Clin. Oncol., July 10, 2007; 25(20): 2884 - 2893. [Abstract] [Full Text] [PDF]

				R. M. Mathew, R. Vandenberghe, A. Garcia-Merino, T. Yamamoto, J. C. Landolfi, M. R. Rosenfeld, J. E. Rossi, B. Thiessen, E. J. Dropcho, and J. Dalmau Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis Neurology, March 20, 2007; 68(12): 900 - 905. [Abstract] [Full Text] [PDF]

				J. W. de Beukelaar and P. A. S. Smitt Managing paraneoplastic neurological disorders. Oncologist, March 1, 2006; 11(3): 292 - 305. [Abstract] [Full Text] [PDF]

				M Tschernatsch, E Stolz, M Strittmatter, M Kaps, and F Blaes Antinuclear antibodies define a subgroup of paraneoplastic neuropathies: clinical and immunological data J. Neurol. Neurosurg. Psychiatry, December 1, 2005; 76(12): 1702 - 1706. [Abstract] [Full Text] [PDF]

				T. Martinu and A. S. Clay A 50-Year-Old Woman With Bilateral Vocal Cord Paralysis and Hilar Mass Chest, August 1, 2005; 128(2): 1028 - 1031. [Full Text] [PDF]

				A. Llado, P. Mannucci, A. F. Carpentier, S. Paris, Y. Blanco, A. Saiz, J. Y. Delattre, and F. Graus Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes Neurology, November 23, 2004; 63(10): 1947 - 1949. [Abstract] [Full Text] [PDF]

				F Graus, J Y Delattre, J C Antoine, J Dalmau, B Giometto, W Grisold, J Honnorat, P S. Smitt, C. Vedeler, J J G M Verschuuren, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes J. Neurol. Neurosurg. Psychiatry, August 1, 2004; 75(8): 1135 - 1140. [Abstract] [Full Text] [PDF]

				R. Linke, M. Schroeder, T. Helmberger, and R. Voltz Antibody-positive paraneoplastic neurologic syndromes: Value of CT and PET for tumor diagnosis Neurology, July 27, 2004; 63(2): 282 - 286. [Abstract] [Full Text] [PDF]

				J H Rees Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage J. Neurol. Neurosurg. Psychiatry, June 1, 2004; 75(suppl_2): ii43 - ii50. [Full Text] [PDF]

				R. Darnell Tumor Immunity in Small-Cell Lung Cancer J. Clin. Oncol., March 1, 2004; 22(5): 762 - 764. [Full Text] [PDF]

				S.E. Monstad, L. Drivsholm, A. Storstein, J.H. Aarseth, M. Haugen, B. Lang, A. Vincent, and C.A. Vedeler Hu and Voltage-Gated Calcium Channel (VGCC) Antibodies Related to the Prognosis of Small-Cell Lung Cancer J. Clin. Oncol., March 1, 2004; 22(5): 795 - 800. [Abstract] [Full Text] [PDF]

				S. Vernino, B. P. O'Neill, R. S. Marks, J. R. O'Fallon, and D. W. Kimmel Immunomodulatory treatment trial for paraneoplastic neurological disorders Neuro-oncol, January 1, 2004; 6(1): 55 - 62. [Abstract] [PDF]

				G. Ragupathi, P. O. Livingston, C. Hood, J. Gathuru, S. E. Krown, P. B. Chapman, J. D. Wolchok, L. J. Williams, R. C. Oldfield, and W.-J. Hwu Consistent Antibody Response against Ganglioside GD2 Induced in Patients with Melanoma by a GD2 Lactone-Keyhole Limpet Hemocyanin Conjugate Vaccine plus Immunological Adjuvant QS-21 Clin. Cancer Res., November 1, 2003; 9(14): 5214 - 5220. [Abstract] [Full Text] [PDF]

				R. B. Darnell and J. B. Posner Paraneoplastic Syndromes Involving the Nervous System N. Engl. J. Med., October 16, 2003; 349(16): 1543 - 1554. [Full Text] [PDF]

				C. A Douglas and J. Ellershaw Anti-Hu antibodies may indicate a positive response to chemotherapy in paraneoplastic syndrome secondary to small cell lung cancer Palliative Medicine, October 1, 2003; 17(7): 638 - 639. [Abstract] [PDF]

				F. Bernal, S. Shams'ili, I. Rojas, R. Sanchez-Valle, A. Saiz, J. Dalmau, J. Honnorat, P. Sillevis Smitt, and F. Graus Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease Neurology, January 28, 2003; 60(2): 230 - 234. [Abstract] [Full Text] [PDF]

				M. Sugita, M. Geraci, B. Gao, R. L. Powell, F. R. Hirsch, G. Johnson, R. Lapadat, E. Gabrielson, R. Bremnes, P. A. Bunn, et al. Combined Use of Oligonucleotide and Tissue Microarrays Identifies Cancer/Testis Antigens as Biomarkers in Lung Carcinoma Cancer Res., July 15, 2002; 62(14): 3971 - 3979. [Abstract] [Full Text] [PDF]

				F. Brichory, D. Beer, F. LeNaour, T. Giordano, and S. Hanash Proteomics-based Identification of Protein Gene Product 9.5 as a Tumor Antigen That Induces a Humoral Immune Response in Lung Cancer Cancer Res., November 1, 2001; 61(21): 7908 - 7912. [Abstract] [Full Text] [PDF]

				F. Graus, F. Keime-Guibert, R. Rene, B. Benyahia, T. Ribalta, C. Ascaso, G. Escaramis, and J. Y. Delattre Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients Brain, June 1, 2001; 124(6): 1138 - 1148. [Abstract] [Full Text] [PDF]

				N.-K. V. Cheung, H.-f. Guo, G. Heller, and I. Y. Cheung Induction of Ab3 and Ab3' Antibody Was Associated with Long-Term Survival after Anti-GD2 Antibody Therapy of Stage 4 Neuroblastoma Clin. Cancer Res., July 1, 2000; 6(7): 2653 - 2660. [Abstract] [Full Text]

				J. C. Darnell, M. L. Albert, and R. B. Darnell cdr2, a Target Antigen of Naturally Occurring Human Tumor Immunity, Is Widely Expressed in Gynecological Tumors Cancer Res., April 1, 2000; 60(8): 2136 - 2139. [Abstract] [Full Text]

				F. Blaes, M. Klotz, H. Huwer, U. Straub, G. Kalweit, K. Schimrigk, and H.-J. Schafers Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer Ann. Thorac. Surg., January 1, 2000; 69(1): 254 - 258. [Abstract] [Full Text] [PDF]

				F. Keime-Guibert, F. Graus, P. Broet, R. Rene, J. L. Molinuevo, C. Ascaso, and J. Y. Delattre Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor Neurology, November 1, 1999; 53(8): 1719 - 1719. [Abstract] [Full Text]

				J. J Verschuuren, M. Perquin, G. ten Velde, M. De Baets, P. v. B. Vriesman, and A. Twijnstra Anti-Hu antibody titre and brain metastases before and after treatment for small cell lung cancer J. Neurol. Neurosurg. Psychiatry, September 1, 1999; 67(3): 353 - 357. [Abstract] [Full Text]

				P. A. Bunn Jr. Immune Therapy for Lung Cancer . Are We Getting Closer? Am. J. Respir. Cell Mol. Biol., July 1, 1999; 21(1): 10 - 12. [Full Text]

				A. Ohwada, I. Nagaoka, F. Takahashi, S. Tominaga, and Y. Fukuchi DNA Vaccination against HuD Antigen Elicits Antitumor Activity in a Small-Cell Lung Cancer Murine Model Am. J. Respir. Cell Mol. Biol., July 1, 1999; 21(1): 37 - 43. [Abstract] [Full Text]

				J. O. Dalmau and J. B. Posner Paraneoplastic Syndromes Arch Neurol, April 1, 1999; 56(4): 405 - 408. [Full Text] [PDF]

				A Saiz, J Dalmau, M H. Butler, Q Chen, J Y Delattre, P De Camilli, and F Graus Anti-amphiphysin I antibodies in patients with paraneoplastic neurological disorders associated with small cell lung carcinoma J. Neurol. Neurosurg. Psychiatry, February 1, 1999; 66(2): 214 - 217. [Abstract] [Full Text]

				N. Sodeyama, K. Ishida, K. A Jaeckle, L. Zhang, A. Azuma, M. Yamada, H. Mizusawa, and Y. Wada Pattern of epitopic reactivity of the anti-Hu antibody on HuD with and without paraneoplastic syndrome J. Neurol. Neurosurg. Psychiatry, January 1, 1999; 66(1): 97 - 99. [Abstract] [Full Text]

				J. O. Dalmau and J. B. Posner Neurological Paraneoplastic Syndromes Neuroscientist, November 1, 1998; 4(6): 443 - 453. [PDF]